Recently, biologics, including anti-tumor necrosis factor, anti-integrin, and anti-interleukin (IL)-12 and IL-23 agents, introduced into anti-IBD pharmacotherapy, have proven to be effective in patients with IBD resistant to conventional drugs [6,7]. Here, TNF is linked to inflammatory bowel disease.